Udenafil: Efficacy and tolerability in the management of erectile dysfunction

Therapeutic Advances in Urology

Volumn 5, Issue 2, 2013, Pages 101-110

  Kang, Sung gu ^a   Kim, je Jong ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Erectile dysfuction; Once daily dosing; Phosphodiesterase type 5; Udenafil

Indexed keywords

AVANAFIL; PLACEBO; SILDENAFIL; TADALAFIL; UDENAFIL; VARDENAFIL;

ARTICLE; COMORBIDITY; CONJUNCTIVAL HYPEREMIA; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; ERECTILE DYSFUNCTION; ETHNICITY; FLUSHING; HEADACHE; HUMAN; HYPERTENSION; MAXIMUM PLASMA CONCENTRATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84876376281     PISSN: 17562872     EISSN: 17562880     Source Type: Journal    
DOI: 10.1177/1756287212470019     Document Type: Review

References (34)

1. Bell A. Palmer M. (2011) Novel phosphodiesterase type 5 modulators: a patent survey (2008–2010). Expert Opin Therapeut Patents 21: 1631–1641.
2. Bollinger K. Lee M. (2005) Recurrent visual field defect and ischemic optic neuropathy associated with tadalafil rechallenge. Arch Ophthalmol 123: 400–401.
3. Braun M. Wassmer G. Klotz T. Reifenrath B. Mathers M. Engelmann U. (2000) Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey–. Int J Impotence Res 12: 305–311.
4. Burchardt M. Burchardt T. Baer L. Kiss A. Pawar R. Shabsigh A. (2000) Hypertension is associated with severe erectile dysfunction. J Urol 164: 1188–1191.
5. Carson C. (2006) Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both? BJU Int 97(Suppl. 2): 39–43; discussion 44–35.
6. Chew K. Earle C. Stuckey B. Jamrozik K. Keogh E. (2000) Erectile dysfunction in general medicine practice: prevalence and clinical correlates. Int J Impotence Res 12: 41–45.
7. Chung B. Lee J. Lee S. Yoo S. Lee S. Oh C. (2009) Safety and efficacy of the simultaneous administration of udenafil and an alpha-blocker in men with erectile dysfunction concomitant with BPH/LUTS. Int J Impotence Res 21: 122–128.
8. Corona G. Mondaini N. Ungar A. Razzoli E. Rossi A. Fusco F. (2011) Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient. J Sexual Med 8: 3418–3432.
9. Cunningham A. Smith K. (2001) Anterior ischemic optic neuropathy associated with Viagra. J Neuro-ophthalmol 21: 22–25.
10. Dean R. Lue T. (2005) Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin N Amer 32: 379–395.
11. Ding H. Du W. Wang H. Zhang L. Wang Z. Du C. (2012) Efficacy and safety of udenafil for erectile dysfunction: a meta-analysis of randomized controlled trials. Urology: 80: 134–139.
12. Dinsmore W. Evans C. (1999) ABC of sexual health: erectile dysfunction. BMJ 318: 387–390.
13. Doh H. Shin C. Son M. Ko J. Yoo M. Kim S. (2002) Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch Pharm Res 25: 873–878.
14. Fusco F. Razzoli E. Imbimbo C. Rossi A. Verze P. Mirone V. (2010) A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibition. BJU Int 105: 1634–1639.
15. Gacci M. Corona G. Salvi M. Vignozzi L. McVary K. Kaplan S. (2012) A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 61: 994–1003.
16. Giuliano F. (2008) Lower urinary tract symptoms and sexual dysfunction: a common approach. BJU Int 101(Suppl. 3): 22–26.
17. Hanson-Divers C. Jackson S. Lue T. Crawford S. Rosen R. (1998) Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol 159: 1541–1547.
18. Hatzimouratidis K. Amar E. Eardley I. Giuliano F. Hatzichristou D. Montorsi F. (2010) Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 57: 804–814.
19. Hayreh S. Joos K. Podhajsky P. Long C. (1994) Systemic diseases associated with nonarteritic anterior ischemic optic neuropathy. Amer J Ophthalmol 118: 766–780.
20. Hoesl C. Woll E. Burkart M. Altwein J. (2005) Erectile dysfunction (ED) is prevalent, bothersome and underdiagnosed in patients consulting urologists for benign prostatic syndrome (BPS). Eur Urol 47: 511–517.
21. Kim B. Lim H. Chung J. Kim J. Lim K. Sohn D. (2008) Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects. Br J Clin Pharmacol 65: 848–854.
22. Kim I. Kim D. (2012) Anterior ischemic optic neuropathy associated with udenafil. Korean J Ophthalmol 26: 235–238.
23. Kouvelas D. Goulas A. Papazisis G. Sardeli C. Pourzitaki C. (2009) PDE5 inhibitors: in vitro and in vivo pharmacological profile. Curr Pharm Des 15: 3464–3475.
24. Lue T. (2000) Erectile dysfunction. N Engl J Med 342: 1802–1813.
25. Montorsi F. Adaikan G. Becher E. Giuliano F. Khoury S. Lue T. (2010) Summary of the recommendations on sexual dysfunctions in men. J Sexual Med 7: 3572–3588.
26. Moon D.G. Yang D. Lee C. Ahn T. Min K. Park K. (2011) A therapeutic confirmatory study to assess the safety and efficacy of Zydena (udenafil) for the treatment of erectile dysfunction in male patients with diabetes mellitus. J Sexual Med 8: 2048–2061.
27. Paick J. Kim S. Park Y. Hyun J. Park N. Lee S. (2009) The efficacy and safety of udenafil [Zydena] for the treatment of erectile dysfunction in hypertensive men taking concomitant antihypertensive agents. J Sexual Med 6(11): 3166–3176.
28. Paick J. Kim S. Yang D. Kim J. Lee S. Ahn T. (2008) The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sexual Med 5: 946–953.
29. Park H.J. Park J.K Park K. Min K. Park N.C. (2010) Efficacy of udenafil for the treatment of erectile dysfunction up to 12 hours after dosing: a randomized placebo-controlled trial. J Sexual Med 7: 2209–2216.
30. Salem E. Kendirci M. Hellstrom W. (2006) Udenafil, a long-acting PDE5 inhibitor for erectile dysfunction. Curr Opin Investigational Drugs 7: 661–669.
31. Shabsigh R. Duval S. Shah M. Regan T. Juhasz M. Veltry L.G. (2007) Efficacy of vardenafil for the treatment of erectile dysfunction in men with hypertension: a meta-analysis of clinical trial data. Curr Med Res Opin 23: 2453–2460.
32. Tsertsvadze A. Yazdi F. Fink H. MacDonald R. Wilt T. Bella A. (2009) Oral sildenafil citrate (Viagra) for erectile dysfunction: a systematic review and meta-analysis of harms. Urology 74: 831–836 e838.
33. Vardi M. Nini A. (2007) Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. Cochrane Database Systematic Rev 1: CD002187.
34. Zhao C. Kim S. Yang D. Kim J. Park N. Lee S. (2011) Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 60: 380–387.